Aficamten in symptomatic obstructive hypertrophic cardiomyopathy: the FOREST-HCM long-term study - PubMed
11 hours ago
- #Hypertrophic cardiomyopathy
- #Aficamten
- #Cardiology
- Aficamten is an oral selective cardiac myosin inhibitor for treating symptomatic obstructive hypertrophic cardiomyopathy (oHCM).
- The FOREST-HCM study evaluated long-term safety and efficacy of aficamten in 296 patients with oHCM.
- Aficamten significantly reduced Valsalva left ventricular outflow tract gradient at Weeks 12 and 96 (56 ± 43 and 62 ± 33 mmHg, respectively).
- Left ventricular ejection fraction (LVEF) showed minimal reduction (-3% ± 6% and -5% ± 5%).
- 69% and 93% of participants experienced at least one NYHA class improvement.
- Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score improved by 15 ± 16 and 16 ± 16 points.
- Treatment-emergent serious adverse events (TESAEs) occurred in 12.2% of patients, with no deaths or heart failure events related to aficamten.
- LVEF <50% occurred in 3.4% of patients, with no events of LVEF <40%.
- New-onset atrial fibrillation occurred in 2.4% of patients.
- Extended aficamten treatment showed sustained hemodynamic and clinical benefits with low incidence of adverse events.